The Market for Drugs and Devices in the Clinical Management of Obesity; A Worldwide Report from MedMarket Diligence, LLC
Foothill Ranch, CA, June 06, 2008 --(PR.com)-- As the growing worldwide problem of obesity becomes more evident, including its commensurate healthcare costs, there is a coinciding proliferation of the number and type of approaches to address the problem. MedMarket Diligence has published its worldwide business report on the products, technologies, markets and companies in the clinical management of obesity.
Technologies for the management of obesity span surgical approaches, medically supervised diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. MedMarket Diligence has maintained a focus on ongoing developments in the field obesity management and has completed a 2007 analysis on the worldwide market for products in the management of obesity.
"The late decision by Sanofi-aventis to withdraw its FDA application for the anti-obesity drug rimonabant, marketed as Acomplia, highlights the need for an effective pharmaceutical treatment for obesity," says Patrick Driscoll, President of MedMarket Diligence. "It is clear that an effective pharmaceutical treatment will hold tremendous potential to compete with all obesity treatment types, but drug prospects have paled compared to current successes of bariatric surgical devices."
The obesity treatment market worldwide is set to grow enormously, and will reach $6.4 billion by 2015. This includes prescription drugs for weight loss and maintenance; devices used in bariatric surgery and follow-up; and the predicted sales of drugs and devices with anticipated launch dates through 2015.
The MedMarket Diligence report on the "Worldwide Market for the Clinical Management of Obesity" describes the clinical trends in the management of the obese, the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy. The report provides a current and forecast market for these products in the U.S., Europe and Rest of World, and profiles key companies in the market, detailing the current products, products in development, market position and overall businesses in obesity management.
The report is described, with complete table of contents and list of exhibits, at http://www.mediligence.com/rpt/rpt-s825.htm.
The report can be purchased directly online (https://www.mediligence.com/store/page22.html)
For additional information, contact Patrick Driscoll, at (949) 859-3401, or patrick {at} mediligence {dot} com.
About MedMarket Diligence
MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes content on advanced medical technologies through Market and Technology Reports (www.mediligence.com/web-files/prod01.htm) and the Medtech Startups Database. (www.mediligence.com/web-files/startups-db.htm).
###
Technologies for the management of obesity span surgical approaches, medically supervised diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. MedMarket Diligence has maintained a focus on ongoing developments in the field obesity management and has completed a 2007 analysis on the worldwide market for products in the management of obesity.
"The late decision by Sanofi-aventis to withdraw its FDA application for the anti-obesity drug rimonabant, marketed as Acomplia, highlights the need for an effective pharmaceutical treatment for obesity," says Patrick Driscoll, President of MedMarket Diligence. "It is clear that an effective pharmaceutical treatment will hold tremendous potential to compete with all obesity treatment types, but drug prospects have paled compared to current successes of bariatric surgical devices."
The obesity treatment market worldwide is set to grow enormously, and will reach $6.4 billion by 2015. This includes prescription drugs for weight loss and maintenance; devices used in bariatric surgery and follow-up; and the predicted sales of drugs and devices with anticipated launch dates through 2015.
The MedMarket Diligence report on the "Worldwide Market for the Clinical Management of Obesity" describes the clinical trends in the management of the obese, the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy. The report provides a current and forecast market for these products in the U.S., Europe and Rest of World, and profiles key companies in the market, detailing the current products, products in development, market position and overall businesses in obesity management.
The report is described, with complete table of contents and list of exhibits, at http://www.mediligence.com/rpt/rpt-s825.htm.
The report can be purchased directly online (https://www.mediligence.com/store/page22.html)
For additional information, contact Patrick Driscoll, at (949) 859-3401, or patrick {at} mediligence {dot} com.
About MedMarket Diligence
MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes content on advanced medical technologies through Market and Technology Reports (www.mediligence.com/web-files/prod01.htm) and the Medtech Startups Database. (www.mediligence.com/web-files/startups-db.htm).
###
Contact
MedMarket Diligence, LLC
Patrick Driscoll
949-859-3401
www.mediligence.com
Patrick Driscoll
949-859-3401
www.mediligence.com
Contact
Categories